Company: APXT
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001213900-25-097069
Chunk: 18

Company: Apex Treasury Corp
Filing Date: 2025-10-07
Form: S-1/A
Chunk 18
---
 Chairman of Celex Oncology Innovations Ltd from 2020 to 2021. He continues to advise boards and leadership teams in sectors including healthcare, technology, and sustainable infrastructure. Mr. Rahman holds a Master of Arts in Law from Pembroke College, University of Cambridge. 3 Hugh Cochrane Jr., Co-Chief Executive Officer Mr. Hugh Cochrane Jr. has served as Co -ChiefExecutive Officer since inception. He is a seasoned executive and investment professional with over 30 years of experience spanning finance, technology, and blockchain innovation. Mr. Cochrane brings a unique combination of institutional investment expertise and technology -drivenentrepreneurship to his role, and he is instrumental in driving the company’s strategic growth and innovation agenda. Mr. Cochrane is currently the Managing Director of SVK Crypto GP and a Director of Cryptogon Management Ltd., positions he has held since co -foundingCryptogon EOS LP in 2018. As one of the pioneers in blockchain venture investing, he played a key role in establishing one of London’s first dedicated blockchain venture capital funds, securing a strategic lead investment from Block.One, one of the world’s leading blockchain infrastructure companies. Under his leadership, Cryptogon has backed transformative blockchain -basedbusinesses, including early investments in Mythical Games and Quantstamp, both of which have achieved valuations exceeding $1 billion. Cryptogon was also an investor in Audigent which had a $363 million exit to Experian. Mr. Cochrane has also developed investment methodologies to identify high -potentialopportunities in the rapidly evolving blockchain and crypto markets. He currently serves on the board of Ordre International, a blockchain -enabledfashion technology company innovating in the luxury retail sector. From 2014 to 2021, Mr. Cochrane was Co -Founderand Director of SVK Capital Management Ltd., a London -basedinvestment advisory firm specializing in IPOs and global equity trading strategies. Prior to that, he founded Villay Asset Management Ltd. in 2000, a firm focused on global equity and fixed income new issues, which he led until 2017. He has also contributed to life sciences innovation as a founding investor and non -executivedirector of Plasticell Ltd., a UK -basedstem cell technology company with a strategic partnership with GlaxoSmithKline (NYSE: GSK), where he served from 2006 to 2018. Earlier in his career, Mr. Cochrane was